11 December 2024 in Pharmacogenomics
Posttransplantation diabetes mellitus (PTDM) is a form of diabetes developed after solid organ or stem cell transplantation. This condition shares physiopathological traits with type 2 diabetes, including insulin resistance and β-cells dysfunction and its prevalence varies significantly based on the diagnostic criteria used. Immunosuppressive drugs directly contribute to PTDM risk through intricate impacts on glucose regulation, insulin secretion, and inflammation. In addition, modifiable and non-modifiable environmental risk factors are associated with the onset of this condition. This review aims to provide a comprehensive overview of the multifactorial nature of PTDM in order to highlight candidate genes and variants for pharmacogenetic research. An extensive literature search was conducted to identify studies on pharmacological and genetic factors influencing PTDM development. This review stresses the importance of understanding these interactions for improving PTDM management and underscores the need for further research to refine preventive approaches, ultimately enhancing patient outcomes post-transplantation.
30 April 2026 in Drug Metabolism and Disposition
Membrane transporters play a central role in the absorption, distribution, metabolism, and elimination of drugs. Beyond drug handling, these transporters regulate the transport of endogenous metabolites, contributing to physiological homeostasis. Their activity is regulated not only by intrinsic cellular mechanisms but also by signals from distant organs. Understanding these processes is crucial for accurately predicting both local and systemic pharmacokinetics, as transporter function influences drug concentrations and effects at target tissues and throughout the organism. However, most current in vitro models do not recapitulate interorgan interactions or the dynamic regulation of transporter function. Microphysiological systems, particularly organ-on-chip, offer a promising approach to studying transporter biology in a more integrated and physiologically relevant context. This review provides an overview of the development and application of organ-on-chip technologies to investigate drug transporters and their regulation. Although significant technical progress has been made, these systems often remain focused on engineering or industrial goals, with limited impact on fundamental biological questions. Moreover, the high degree of customization and widespread use of homemade organ-on-chip models, with diverse materials, geometries, and cell sources, have created substantial barriers to reproducibility and cross-laboratory comparison. We here assess the current state of the field and identify gaps in modeling transporter regulation and interorgan communication. We also explore the potential of organ-on-chip to advance our understanding of systemic pharmacology. This review aims to reposition organ-on-chip platforms not only as technological demonstrators but also as experimental systems capable of generating new biological insights into transporter function and organ crosstalk. SIGNIFICANCE STATEMENT: Membrane transporters are central regulators of drug disposition and systemic homeostasis, yet their interorgan regulation remains poorly captured by conventional models. This review highlights how organ-on-chip technologies can bridge this gap, enabling mechanistic investigation of transporter function and advancing predictive, human-relevant pharmacology.
18 June 2026 in Therapeutic Drug Monitoring
Background: Pharmacogenetics (PGx) is increasingly recognized as an important component of personalized medicine. In kidney transplantation, where immunosuppressive therapies and comedications often have narrow therapeutic index, preemptive PGx could complement therapeutic drug monitoring to improve individualized care. This study aimed to investigate the value of implementing PGx testing in the pretransplant assessment of renal transplant recipients. Methods: This single-center retrospective study included 110 adult patients who underwent a pretransplant PGx assessment between January 1, 2022, and June 30, 2023. The analysis focused on 16 pharmacogenes shared between the local routine PGx panel and the publicly available ClinPGx guideline support interface, with some genes analyzed using hotspot-only coverage. Medication lists were extracted at 2 time points: pretransplant and post-transplant (or last follow-up for patients on waiting list). Theoretical actionability was defined as the presence of at least 1 actionable genotype, and effective actionability as at least 1 actionable gene–drug pair according to international guidelines. Results: Theoretical actionability was observed in 109 of 110 patients (99%). Effective actionability concerned 29 of 110 patients (26%) at the pretransplant assessment and 19 of 41 (46%) at the post-transplant stage. The most frequent actionable gene–drug pairs at the latter stage included CYP2C19- proton pump inhibitors (38%), CYP3A5 -tacrolimus (25%), SLCO1B1- statins (13%), CYP2D6-tramadol (8%), and ABCG2 -allopurinol (8%). Conclusions: Preemptive PGx embedded in the pretransplant evaluation identifies clinically relevant gene–drug interactions. In combination with therapeutic drug monitoring, this approach has the potential to optimize immunosuppressive drugs initiation and support pharmacological management in kidney transplantation.